Robert Hermann

Robert Hermann, MD, FCP

Robert underwent medical training at the Johann-Wolfgang-Goethe University in Frankfurt and obtained his M.D. (1982) and Ph.D. (1984). Thereafter, he specialised and earned accreditations as a board certified Anaesthesiologist and Clinical Pharmacologist.  After 8 years in clinical medicine, he joined the pharmaceutical industry in 1990 and assumed over the years various expert and managing functions of increasing responsibility in Clinical Pharmacology, Translational- and Exploratory-Medicine, including VP and CMO roles. He and his teams contributed significantly to the clinical development and international regulatory approval of several products, including three “first-in-class” NMEs.

The scientific activities of Robert in the field of early clinical drug development are reflected by contributions to more than 90 publications, reviews, and book articles. He serves also as member of the Editorial Board of the Journal of Clinical Pharmacology, and as acting reviewer for various international Clinical Pharmacology and Clinical Pharmacokinetic Peer Journals.

Robert is Fellow of the American College of Clinical Pharmacology (FCP), founder member of the Association for Applied Human Pharmacology (AGAH), and member of the German Society for Clinical Pharmacology & Therapeutics (DGKliPha), the European Respiratory Society (ERS), and the International Society for Aerosols in Medicine (ISAM).

He also served as a member and Chair of the Board of Trustees of the Fraunhofer Institute for Toxicology & Experimental Medicine (ITEM), Hannover, Germany, for more than a decade. In this capacity, Robert mentored the foundation of a dedicated respiratory experimental medicine group at ITEM, as well as the establishment of an environmental exposure unit for the conduct of well standardized allergen challenge studies (e.g. pollen studies in allergic rhinitis, etc.).

Robert is also co-founder and Faculty Member of the International Marbach Castle Drug-Drug Interaction Workshop series (established in 2010), which is dedicated to improve and disseminate the scientific knowledge about regulatory requirements and current scientific aspects on the preclinical and clinical investigation of drug-drug interactions.

Since 2008, Robert runs his own business and serves as an independent consultant to the pharmaceutical and biotech industry in the field of early clinical development as owner and managing director of cr.appliance (